Frexalimab
Frexalimab is an second-generation monoclonal antibody for the treatment of relapsing multiple sclerosis, under developement by Sanofi. Mechanism of action It is a CD40 ligand inhibitor. See also Antibody Monoclonal antibody Immunology References Breakthrough therapy Monoclonal antibodies